Systemic immune profiling uncovers divergent mechanisms and predictive biomarkers of response to combination immunotherapies in hepatocellular carcinoma.
1/5 보강
[BACKGROUND] Combination immunotherapies such as atezolizumab plus bevacizumab (Atez/Bev) and durvalumab plus tremelimumab (Dur/Tre) improve outcomes in advanced hepatocellular carcinoma (HCC), yet sy
APA
Nishio A, Kodama T, et al. (2026). Systemic immune profiling uncovers divergent mechanisms and predictive biomarkers of response to combination immunotherapies in hepatocellular carcinoma.. Journal for immunotherapy of cancer, 14(3). https://doi.org/10.1136/jitc-2025-013648
MLA
Nishio A, et al.. "Systemic immune profiling uncovers divergent mechanisms and predictive biomarkers of response to combination immunotherapies in hepatocellular carcinoma.." Journal for immunotherapy of cancer, vol. 14, no. 3, 2026.
PMID
41912268 ↗
Abstract 한글 요약
[BACKGROUND] Combination immunotherapies such as atezolizumab plus bevacizumab (Atez/Bev) and durvalumab plus tremelimumab (Dur/Tre) improve outcomes in advanced hepatocellular carcinoma (HCC), yet systemic immune mechanisms underlying response remain incompletely defined.
[METHODS] We performed single-cell RNA sequencing with CITE-seq on peripheral blood mononuclear cells from 19 advanced HCC patients (Atez/Bev: 5 responders (R), 5 non-responders (NR); Dur/Tre: 4 R, 5 NR) before and during treatment, yielding 345 962 single-cell transcriptomes spanning 22 immune cell clusters. Analysis included transcriptional profiling, gene set enrichment analysis, T cell receptor (TCR) repertoire analysis, and CellChat-based intercellular communication modeling.
[RESULTS] Baseline comparisons revealed distinct systemic immune states by etiology: non-viral HCC exhibited CD8 T cells with heightened cytotoxic and memory-associated signatures. Under Atez/Bev, CD14 monocytes in responders were reprogrammed toward antigen-presenting and lymphocyte-supporting functions, while PRKCH NK cells acquired a robust cytotoxic program reinforced by monocyte-NK interactions via ICAM-integrin and HLA-E-NKG2C axes. In contrast, Dur/Tre responders exhibited CD14 monocyte programs enriched in inflammatory and interferon-driven antigen presentation, alongside transcriptional reprogramming of CD8 central memory T cells into an effector-ready state with strong crosstalk to monocytes. TCR analysis revealed regimen-specific differences: clonotype expansion occurred irrespective of response under Atez/Bev, whereas Dur/Tre responders showed both clonotype expansion and higher pretreatment CD8 T cell diversity, with expanded clones displaying cytotoxic and interferon-responsive profiles. Pretreatment immune composition, including naïve CD4 T cells and PRKCH NK cells for Atez/Bev and conventional dendritic cells for Dur/Tre, also predicted response.
[CONCLUSIONS] Our findings reveal regimen-specific systemic immune mechanisms in advanced HCC: Atez/Bev amplifies monocyte-NK cytotoxic axes, whereas Dur/Tre enhances monocyte-T cell inflammatory networks and TCR repertoire diversity. These insights highlight distinct predictive biomarkers and support regimen-tailored immunotherapy in HCC.
[METHODS] We performed single-cell RNA sequencing with CITE-seq on peripheral blood mononuclear cells from 19 advanced HCC patients (Atez/Bev: 5 responders (R), 5 non-responders (NR); Dur/Tre: 4 R, 5 NR) before and during treatment, yielding 345 962 single-cell transcriptomes spanning 22 immune cell clusters. Analysis included transcriptional profiling, gene set enrichment analysis, T cell receptor (TCR) repertoire analysis, and CellChat-based intercellular communication modeling.
[RESULTS] Baseline comparisons revealed distinct systemic immune states by etiology: non-viral HCC exhibited CD8 T cells with heightened cytotoxic and memory-associated signatures. Under Atez/Bev, CD14 monocytes in responders were reprogrammed toward antigen-presenting and lymphocyte-supporting functions, while PRKCH NK cells acquired a robust cytotoxic program reinforced by monocyte-NK interactions via ICAM-integrin and HLA-E-NKG2C axes. In contrast, Dur/Tre responders exhibited CD14 monocyte programs enriched in inflammatory and interferon-driven antigen presentation, alongside transcriptional reprogramming of CD8 central memory T cells into an effector-ready state with strong crosstalk to monocytes. TCR analysis revealed regimen-specific differences: clonotype expansion occurred irrespective of response under Atez/Bev, whereas Dur/Tre responders showed both clonotype expansion and higher pretreatment CD8 T cell diversity, with expanded clones displaying cytotoxic and interferon-responsive profiles. Pretreatment immune composition, including naïve CD4 T cells and PRKCH NK cells for Atez/Bev and conventional dendritic cells for Dur/Tre, also predicted response.
[CONCLUSIONS] Our findings reveal regimen-specific systemic immune mechanisms in advanced HCC: Atez/Bev amplifies monocyte-NK cytotoxic axes, whereas Dur/Tre enhances monocyte-T cell inflammatory networks and TCR repertoire diversity. These insights highlight distinct predictive biomarkers and support regimen-tailored immunotherapy in HCC.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.